EN DE
Watch Gwo Xi Stem Cell Applied Technology Co. , Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Gwo Xi Stem Cell Applied Technology Co. , Ltd stock TWD 2.66, price TWD 20.15, that is 86.8% below the price, quality 41 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW · ISIN TW0006704000

GX Gwo Xi Stem Cell Applied Technology Co. , Ltd logo Thin data Nov 9, 2026

Gwo Xi Stem Cell Applied Technology Co. , Ltd

6704 · TWO
Weakest Setup

Our calculation puts a fair price 87% below what the stock costs today.

Low debt
Quality 41/100
Revenue last quarter 31% below a year ago.
Fair value 2.66 TWD · Strongly overvalued
Weak Growth (revenue 5y −0.2 %/yr in TWD)
Loss-making · -62.7% net margin (TTM)
Negative free cash flow
Trails peers (2/10)
Narrow moat 8/100 · thin data
Thin data
Watch Gwo Xi Stem Cell Applied Technology Co. , Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

28.15 TWD 18.80 TWD Fair Value 2.66 TWD Dec 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

11‑month range 18.80 TWD – 28.15 TWD · fair‑value band 1.98 TWD – 3.96 TWD · the 20.15 TWD price screens above the 2.66 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow Gwo Xi Stem Cell Applied Technology Co. in your weekly email

Every Wednesday you see whether Gwo Xi Stem Cell Applied Technology Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Gwo Xi Stem Cell Applied Technology Co. , Ltd develops stem cell technology for patients with unmet medical needs.

Show moreShow less

Its products under development include GXHPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of liver cirrhosis; and GXNPC1, an autologous adipose-derived stem cell therapy in phase II clinical trials for use in the treatment of chronic stroke.

The company is also developing GXCPC1, an allogeneic adipose-derived stem cells therapy in phase I/II clinical trials for use in the treatment of osteoarthritis; and GXIPC1, an allogeneic adipose-derived stem cells therapy in phase I clinical trials for use in the treatment of diabetes.

The company was founded in 2011 and is based in Zhubei, Taiwan.

Stock analysis

Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) currently trades at 20.15 TWD, while our model-based Fair Value estimate is 2.66 TWD, 87% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 1.98 TWD (bear) to 3.96 TWD (bull), the price of 20.15 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak: less than 2 % a year.

Gwo Xi Stem Cell Applied Technology Co. , Ltd reported revenue of 187M TWD in FY2025 versus 243M TWD in FY2021, a compound −6.3%/yr. Reported net income was −80.5M TWD in FY2025.

Key figures

Market cap 2.2B TWD (≈ $66.7M) Micro · P/S ratio 14.5 · EPS (TTM) −1.04 TWD · Net margin −62.7% · Return on equity −14.4% · Return on assets (EBIT) −8.5% (5-year average) · Operating margin −76.7% · Revenue (TTM) 158M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).

What moves the price

The share trades about 28% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −87%, 6704 screens richer than that median.

Fair Value models

Bear 1.98 TWD Fair Value 2.66 TWD Bull 3.96 TWD
Price 20.15 TWD · Downside -86.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 1.98 TWD 2.66 TWD 3.96 TWD 54
All 1 models by family
Asset-Based
NCAV (Graham) 1.98 TWD 2.66 TWD 3.96 TWD 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 6
How much profit the company makes from its sales and capital
Quality Growth 59
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 82
Debt, balance sheet and risk of trouble
Investment 59
Does it invest with discipline instead of growing at any price?
Low Volatility 83
How calm the share price moves, does not count
Price momentum 42
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 8
Distance to the 52-week high, does not count
New shares 61
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 4/100
Revenue growth is weak: less than 2 % a year.
Revenue growth 1 year
+10.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.2%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−39.5% (2020) → −39.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6704 screens overvalued: fair value 87% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Gwo Xi Stem Cell Applied Technology Co. , Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 41 · Below median
Fair Value upside −86.7% · Bottom 25%
Profitability
Return on assets −8.2% · Above median
Net margin (12 months) −62.7% · Bottom 25%
Operating margin (12 months) −76.7% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −30.9% · Bottom 25%
Balance sheet
Debt / equity 0.42× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 3.75× · Priciest 25%
P/S (12 months) 13.77× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)79 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 6704
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 6704
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 6704
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 6704
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs 6704
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 6704
argenx SE ARGX $927.21 $908.40 −2% vs 6704
CSL Limited CSL A$200.77 A$183.04 −9% vs 6704
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 6704
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 6704

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Gwo Xi Stem Cell Applied Technology Co. , Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Gwo Xi Stem Cell Applied Technology Co. , Ltd Fair Value". https://www.fairvalue-calculator.com/stock/6704

Frequently asked questions

Is Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 2.66 TWD versus a price of 20.15 TWD, about 87% lower (overvalued).
What is the fair value of 6704?
Our model-based fair value for Gwo Xi Stem Cell Applied Technology Co. , Ltd is 2.66 TWD (as of Nov 9, 2026), built from audited fundamentals. The current price: 20.15 TWD.
What is the quality score of 6704?
Gwo Xi Stem Cell Applied Technology Co. , Ltd has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
Our model-based price target is the fair value of 2.66 TWD (as of Nov 9, 2026) from 1 valuation models. Cautious scenario 1.98 TWD, optimistic scenario 3.96 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the Gwo Xi Stem Cell Applied Technology Co. , Ltd stock forecast for 2026?
Our models put fair value at 2.66 TWD, about 87% lower versus a price of 20.15 TWD (overvalued). Cautious scenario 1.98 TWD, optimistic scenario 3.96 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
Gwo Xi Stem Cell Applied Technology Co. , Ltd reported trailing-twelve-month revenue of about 158M TWD (latest available figure, as of Nov 9, 2026).
What is the intrinsic value of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Gwo Xi Stem Cell Applied Technology Co. , Ltd it is 2.66 TWD per share (as of Nov 9, 2026), against a price of 20.15 TWD. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Gwo Xi Stem Cell Applied Technology Co. , Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 6704 trades above its calculated fair value: price 20.15 TWD, fair value 2.66 TWD, a gap of about −87% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6704?
No. The price is what the market pays today (20.15 TWD); the fair value is what the company's own numbers justify (2.66 TWD). For Gwo Xi Stem Cell Applied Technology Co. , Ltd the two are 17.49 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Gwo Xi Stem Cell Applied Technology Co. , Ltd worth?
The market values Gwo Xi Stem Cell Applied Technology Co. , Ltd at about 2.2B TWD (market capitalisation, as of Nov 9, 2026). Per share that is 20.15 TWD; our models calculate a fair value of 2.66 TWD per share.
What do the bullish and bearish scenarios say about 6704?
Our models span a range for Gwo Xi Stem Cell Applied Technology Co. , Ltd: cautious scenario 1.98 TWD, base 2.66 TWD, optimistic 3.96 TWD per share (as of Nov 9, 2026, price 20.15 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
Balance-sheet figures for Gwo Xi Stem Cell Applied Technology Co. , Ltd (as of Nov 9, 2026): return on equity −14.4%, debt of 0.42 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is 6704 from its 52-week high?
Gwo Xi Stem Cell Applied Technology Co. , Ltd trades at 20.15 TWD, about 28% below its 52-week high of 28.15 TWD and 7% above the low of 18.80 TWD (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 2.66 TWD is for.
Which stocks are comparable to Gwo Xi Stem Cell Applied Technology Co. , Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Gwo Xi Stem Cell Applied Technology Co. , Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 20.15 TWD, calculated fair value 2.66 TWD (−87%), Quality Score 41/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6704 calculated?
We run Gwo Xi Stem Cell Applied Technology Co. , Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 2.66 TWD builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Gwo Xi Stem Cell Applied Technology Co. , Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
The closing price on Nov 9, 2026 was 20.15 TWD. Our model-based fair value is 2.66 TWD, about 87% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Gwo Xi Stem Cell Applied Technology Co. , Ltd right now?
The price sits above even our optimistic bull case (3.96 TWD). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (1.98 TWD to 3.96 TWD) leaves room in how you read the outcome.

Key figures of Gwo Xi Stem Cell Applied Technology Co. , Ltd

How large is the market capitalisation of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
The market capitalisation of Gwo Xi Stem Cell Applied Technology Co. , Ltd is 2.2B TWD (≈ $66.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
The price-to-sales ratio of Gwo Xi Stem Cell Applied Technology Co. , Ltd is 14.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
Earnings per share at Gwo Xi Stem Cell Applied Technology Co. , Ltd are −1.04 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
The net margin of Gwo Xi Stem Cell Applied Technology Co. , Ltd is −62.7% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
The return on equity (ROE) of Gwo Xi Stem Cell Applied Technology Co. , Ltd is −14.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
On an EBIT basis the return on assets of Gwo Xi Stem Cell Applied Technology Co. , Ltd is −8.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
The operating margin of Gwo Xi Stem Cell Applied Technology Co. , Ltd is −76.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704)?
Revenue at Gwo Xi Stem Cell Applied Technology Co. , Ltd is growing −30.9% versus a year earlier (3y avg +1.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) generate?
The free cash flow of Gwo Xi Stem Cell Applied Technology Co. , Ltd is −80.7M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Gwo Xi Stem Cell Applied Technology Co. , Ltd (6704) carry?
The net debt of Gwo Xi Stem Cell Applied Technology Co. , Ltd is 129M TWD (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Gwo Xi Stem Cell Applied Technology Co. , Ltd in the live analysis

One click puts Gwo Xi Stem Cell Applied Technology Co. , Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.